IntellxxDNA

Operations

Empowering clinicians with genomics-based insights to improve patient outcomes and personalize care.

Services
  • Clinical Decision Support Tool
  • Health Focused Genomic Reports
Location Austin, Texas
About

IntellxxDNA

In an era where precision is paramount, IntellxxDNA is revolutionizing the way physicians approach healthcare decisions. Unlike traditional genomics tools that focus solely on pharmacogenomics, cancer genomics, or rare diseases, IntellxxDNA provides a comprehensive solution for managing multifactorial chronic conditions such as heart disease, diabetes, cognitive decline, mental health issues, and autism, among others. By enabling physicians to identify and address the root causes of diseases, IntellxxDNA not only improves prevention and treatment but also reduces the cost of healthcare.

What sets IntellxxDNA apart is its ability to make genomics truly actionable. IntellxxDNA empowers physicians to implement personalized, precise treatment plans by reporting on gene variants with well-understood functions and pairing them with targeted potential interventions, including diet, lifestyle modifications, supplements and medications. This innovative approach is already being utilized by top physicians across the US to enhance patient outcomes and satisfaction and is being utilized in three IRB-approved trials focused on improving outcomes in cognitive decline and children with complex illness.

Unlock exclusive discounts and offers from IntellxxDNA and other trusted partners with an SSRP Pro Membership.
What People Say

Testimonials

I wanted to add my two cents worth in support of IntellxxDNA and Dr Sharon Hausman-Cohen MD, et al, as a Trusted Partner with SSRP. I have used different genetics companies in my practices since 2010, starting with Kendal Stewart, MD, working the actionable SNP’s to improve health in my patients care. Over the years I never really found a platform that provided relevant clinical guidance with all of the evidence backed research at your fingertips prior to engaging with Dr Hausman-Cohen and IntellxxDNA. I was so impressed I recommend this company to Dr Seeds as one of the missing pieces in the Cellular Medicine puzzle. Dr Seeds got back to me and expressed is thanks for introducing Dr Hausman-Cohen. He said that she was the first doctor that could answer all his questions and provide a workable clinical platform to make the complex useful and improve the clinical success that SSRP Members are looking for. I have attended their monthly case studies, worked with their trainers on my complex patients and can say their support is excellent, the guidance is clinically valuable and adding IntellxxDNA to the Trusted Partners will be a valuable benefit for our Membership.

Kenton Crowley, Pharm.D., ABAAHP, FAARFM, CEO, President Palliative Care Consultants, LLC.; Crowley Consultants, Inc.
Network with our partners

Upcoming Events

View Upcoming Events
EVENT
Peptide Therapy Certification 2026
September 11 - 12, 2026

Peptide Therapy Certification 2026

View Event Details
RESOURCES

Join us in breaking down the latest research live.

VIEW ALL
PODCAST
Redox Revolution
Sep 1, 2026
Ep.75 – Alcohol: The Facts about Use and Abuse
Ep.75 – Alcohol: The Facts about Use and Abuse

In this episode of Redox Revolution, Dr. Seeds addresses the misinformation about alcohol and clarifies common misunderstandings related to alcohol’s immediate and long-term effects on the brain and the body and the distinctions between abuse and addiction.

Brain & Cognition · Longevity & Healthspan
VIDEO
Cellular Medicine Mondays
Aug 31, 2026
Ep. 103 - Liposomal Peptides
Preview Only
Dissecting Protocols – Episode 103

Liposomal Peptides

Dr. Seeds takes a closer look at liposomal peptides, including Epitalon, BPC-157, TB4, KPV, and GHK-Cu, and examines the claims around sourcing, stability, absorption, bioavailability, injection fatigue, and whether these formulations can truly compare to injectable peptides.

Preview Only — Become a member for full access
SSRP Institute Aug 27, 2026
Rasonque: An FDA-Approved Drug to Treat Pancreatic Cancer
BREAKING NEWS August 26, 2026 – The Food and Drug Administration on Wednesday approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma, the most common form of pancreatic cancer and one long considered among the hardest to treat. The once-daily tablet, developed by Revolution Medicines, is the first targeted therapy approved for the […]
READ NEWS
SSRP Institute Aug 21, 2026
Alpha-Gal Syndrome: An Update on Incidence Rate by the CDC
HEADLINE SCIENCE JAMA recently published a report about the incidence rate of alpha-gal syndrome, which is a serious allergic reaction to a sugar molecule called alpha-gal, which is found in most mammals. It is typically transmitted through a bite from a Lone Star tick or other tick species that injects the molecule into the body, […]
READ NEWS
IntellxxDNA Aug 12, 2026
SSRP Institute Welcomes IntellxxDNA as New Trusted Partner
PARTNER ANNOUNCEMENT WILLOUGHBY, Ohio, [August 12, 2026] — The SSRP Institute welcomes IntellxxDNA to its Trusted Partner Network following a nomination and internal vetting process, aligning with SSRP’s mission to advance science-first, education-driven clinical collaboration. IntellxxDNA provides clinicians with a structured genomic decision support platform that translates complex genetic data into clinically actionable insights. Using […]
READ NEWS
ARTICLE
William Seeds, MD
Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
William Seeds, MD Aug 6, 2026
A Lipid at the Root of Mitochondrial Aging: Phosphatidylcholine, Methylation, and a Malleable Therapeutic Window
Mitochondrial dysfunction is one of the most firmly established hallmarks of aging, but the field has spent far more energy describing genetic causes of mitochondrial failure—mtDNA mutation, defective OXPHOS, impaired unfolded protein response—than the “natural” drivers that erode mitochondria during ordinary aging. As I discussed in my recent June Journal Club (as well as a […]
READ ARTICLE
SSRP Institute Jul 24, 2026
PCAC Meeting Vote Summary
BREAKING NEWS JULY 24, 2026 – The Pharmacy Compounding Advisory Committee (PCAC) has completed its July session, voting on several peptide bulk drug substances for potential inclusion on the FDA’s 503A Bulks List.Recommended FOR inclusion: (Yes-No)• BPC-157 (8–6)• KPV (8–6)• TB-500 (8–6)• MOTS-c (7–5)• Epitalon (7–4)• Semax (8–5)Recommended AGAINST inclusion: (Yes-No)• DSIP (6–7) What happens […]
READ NEWS
ARTICLE
William Seeds, MD
Jul 14, 2026
The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Blood Pressure Regulation
William Seeds, MD Jul 14, 2026
The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Blood Pressure Regulation
After a recent Journal Club episode in which I featured, The Renin–Angiotensin–Aldosterone System (RAAS): Beyond Cardiovascular Regulation, I wanted to return to the article and expand a bit on the significance of the Renin–Angiotensin–Aldosterone System (RAAS). As we know, the RAAS system has traditionally been viewed as the body’s primary mechanism for regulating blood pressure, […]
READ ARTICLE
World Congress World Congress
Peptide World Congress 2026
At Peptide World Congress 2026, join the fastest-growing community of evidence-based providers exploring the therapeutic power of clinical peptides. Learn why the body ages, when disease originates, and how top clinicians are changing their patients’ lives by treating the body...
22 Lessons
13 Hours 10 Minutes
View Course